Nav: Home

Dana-Farber/Boston Children's opens immunotherapy trial for children with leukemia

May 11, 2015

BOSTON (May 11, 2015)--Dana-Farber/Boston Children's Cancer and Blood Disorders Center has joined a clinical trial of immunotherapy for children with relapsed or treatment-resistant acute lymphoblastic leukemia (ALL). Led by Memorial Sloan Kettering Cancer Center (MSKCC), the trial is one of several nationally that are evaluating cancer immunotherapy, a treatment approach -- hailed by Science magazine as their Breakthrough of the Year in 2013 -- that triggers a patient's immune system to attack his or her cancer cells. Dana-Farber/Boston Children's is the only site in New England to offer this experimental approach for children and adolescents whose ALL has relapsed multiple times or never gone into remission.

The innovative trial starts with a patient's own infection-fighting T-cells. These cells are collected and modified using gene therapy techniques to produce a cancer-hunting protein called a chimeric antigen receptor (CAR). Once infused back into the patient, the CAR then prompts the modified T-cells to attack leukemia cells by seeking out and recognizing a protein they carry on their surface. The CAR also spurs the modified T-cells to divide and grow once they come in contact with ALL cells, fueling a more robust immune response.

"There has been evidence for many years that the immune system can be used to help control leukemia, but we have yet to find the best way to harness it to treat disease," said Lewis Silverman, MD, clinical director of the Hematologic Malignancies Center at Dana-Farber/Boston Children's and the local lead investigator on the trial. "CAR-modified T-cell clinical trials have shown promising results in adults and children with leukemias, and we are very excited to test this treatment in children and adolescents with ALL."

This pediatric CAR T-cell trial is available only at Dana-Farber/Boston Children's and MSKCC. The trial is open to patients up to age 26 with relapsed B-cell ALL who have not yet undergone a hematopoietic stem cell transplant. The trial joins Dana-Farber/Boston Children's already robust portfolio of clinical trials for both leukemia and gene therapy.

Approximately 2,900 children in the United States are diagnosed each year with ALL, the most common cancer of childhood. Although 80-90 percent of patients go on to become long-term survivors, 15-20 percent of children who achieve an initial complete remission later experience a relapse. The prognosis for these patients depends on a number of factors, including the site of relapse, length of time between initial diagnosis and relapse, and biological features of the relapsed cells.

The Phase I trial is the first clinical step in the Food and Drug Administration's process for approving a new drug or treatment. The goal is to establish the treatment's safety in a small group of patients, with an eye toward larger studies of safety and efficacy should the Phase I trial succeed. Each trial participant will be followed very closely for side effects as well as treatment response. Because the trial involves gene therapy, participants will be followed for 15 years following treatment.

Detailed information about the trial, including eligibility criteria, is available on ( Questions about eligibility should be directed to
The Dana-Farber/Boston Children's Cancer and Blood Disorders Center brings together two internationally known research and teaching institutions that have provided comprehensive care for pediatric oncology and hematology patients since 1947. The Harvard Medical School affiliates share a clinical staff that delivers inpatient care at Boston Children's Hospital and outpatient care at the Dana-Farber Cancer Institute's Jimmy Fund Clinic. Dana-Farber/Boston Children's brings the results of its pioneering research and clinical trials to patients' bedsides through five clinical centers: the Blood Disorders Center, the Brain Tumor Center, the Hematologic Malignancies Center, the Solid Tumors Center and the Stem Cell Transplant Center.

Dana-Farber Cancer Institute

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".